Vertex Pharma (VRTX) Tops Q3 EPS by 39c; Raises Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Vertex Reports Third Quarter 2022 Financial Results
October 27, 2022 4:01 PM EDTProduct revenue of $2.33 billion, an 18% increase compared to Q3 2021
Company increases full year 2022 product revenue guidance to $8.8 billion to $8.9 billion
Significant progress in mid- and late-stage pipeline, with near-term commercialization opportunities:
Initiating global exa-cel regulatory submissions for Sickle Cell Disease and Beta Thalassemia in 2022
Initiated Phase 3 clinical studies of VX-548, a novel, selective NaV1.8 inhibitor, in acute pain
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third... More
